Gene Editing beyond CRISPR Market

  Treg based therapies have become a research hotspot in the field of immunotherapy due to their ability to prevent / delay graft rejection and control autoimmune responses generated post adoptive transfer in vivo   Roots Analysis has announced the addition of “ Regulatory T-Cell (Tregs) Therapies Market, 2021 – 2035 ” report to its list of offerings.   The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapies over the next decade. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes: §   A detailed assessment of the current market landscape of drug developers engaged in the development of regulatory T-cell therapies .  §   A detailed analysis of more than 180+ completed, ongoing and planned clinical studies of regulatory T-cell therapies. §   Det...

  With the approval of HUMULIN®, the first genetically modified drug, scientific community has made significant progress in developing gene edited therapies based on programmable nucleases, such as ZFNs, TALENs, EMNs and CRISPR   London   Roots Analysis has announced the addition of “ Gene-Editing Beyond CRISPR: Focus on ZFN, TALENs and Meganucleases Market, 2021-2035 ” report to its list of offerings.   The ability of gene editing solutions to directly target and modify genomic sequences has greatly expedited the progress of gene editing therapies into clinical stages. The clinical trials data of ZFNs, TALENs and meganucleases based therapies demonstrate their potential in the treatment of various diseases, including infectious diseases and oncological disorders. In addition, several product candidates are being evaluated in discovery and preclinical stages of development for hematological disorders, genetic disorders and neurological disorders. ...